171 related articles for article (PubMed ID: 16421722)
21. HLA-G expression in malignant melanoma.
Rebmann V; Wagner S; Grosse-Wilde H
Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098
[TBL] [Abstract][Full Text] [Related]
22. Lymphocyte-melanoma interaction: role of surface molecules.
Becker JC; Bröcker EB
Recent Results Cancer Res; 1995; 139():205-14. PubMed ID: 7597291
[TBL] [Abstract][Full Text] [Related]
23. Broadening the repertoire of melanoma-associated T-cell epitopes.
Frøsig TM; Lyngaa R; Met Ö; Larsen SK; Donia M; Svane IM; Thor Straten P; Hadrup SR
Cancer Immunol Immunother; 2015 May; 64(5):609-20. PubMed ID: 25854582
[TBL] [Abstract][Full Text] [Related]
24. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms.
Chang CC; Murphy SP; Ferrone S
Hum Immunol; 2003 Nov; 64(11):1057-63. PubMed ID: 14602236
[TBL] [Abstract][Full Text] [Related]
25. In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele.
Real LM; Jimenez P; Cantón J; Kirkin A; García A; Abril E; Zeuthen J; Ruiz-Cabello F; Garrido F
Int J Cancer; 1998 Jan; 75(2):317-23. PubMed ID: 9462725
[TBL] [Abstract][Full Text] [Related]
26. Analysis of HLA-E expression in human tumors.
Marín R; Ruiz-Cabello F; Pedrinaci S; Méndez R; Jiménez P; Geraghty DE; Garrido F
Immunogenetics; 2003 Feb; 54(11):767-75. PubMed ID: 12618909
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.
Carrega P; Pezzino G; Queirolo P; Bonaccorsi I; Falco M; Vita G; Pende D; Misefari A; Moretta A; Mingari MC; Moretta L; Ferlazzo G
PLoS One; 2009 Dec; 4(12):e8132. PubMed ID: 19997637
[TBL] [Abstract][Full Text] [Related]
28. High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines.
Hurks HM; Metzelaar-Blok JA; Mulder A; Claas FH; Jager MJ
Int J Cancer; 2000 Mar; 85(5):697-702. PubMed ID: 10699951
[TBL] [Abstract][Full Text] [Related]
29. HLA-G expression: immune privilege for tumour cells?
Cabestre FA; Lefebvre S; Moreau P; Rouas-Friess N; Dausset J; Carosella ED; Paul P
Semin Cancer Biol; 1999 Feb; 9(1):27-36. PubMed ID: 10092548
[TBL] [Abstract][Full Text] [Related]
30. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
[TBL] [Abstract][Full Text] [Related]
31. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.
Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S
Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004
[TBL] [Abstract][Full Text] [Related]
32. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression.
Wang Z; Margulies L; Hicklin DJ; Ferrone S
Tissue Antigens; 1996 May; 47(5):382-90. PubMed ID: 8795138
[TBL] [Abstract][Full Text] [Related]
33. TypeLoader: A fast and efficient automated workflow for the annotation and submission of novel full-length HLA alleles.
Surendranath V; Albrecht V; Hayhurst JD; Schöne B; Robinson J; Marsh SGE; Schmidt AH; Lange V
HLA; 2017 Jul; 90(1):25-31. PubMed ID: 28503844
[TBL] [Abstract][Full Text] [Related]
34. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019
[TBL] [Abstract][Full Text] [Related]
35. HLA class I antigens in Japanese patients with melanoma.
Kageshita T; Naruse T; Hirai S; Horikoshi T; Nakagawa H; Tamaki K; Hayashibe K; Ichihashi M; Nakayama J; Hori Y; Ozawa A; Miyahara M; Ohkido M; Inoko H; Ono T
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):428-32. PubMed ID: 9041462
[TBL] [Abstract][Full Text] [Related]
36. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.
Dunnion DJ; Cywinski AL; Tucker VC; Murray AK; Rickinson AB; Coulie P; Browning MJ
Immunology; 1999 Dec; 98(4):541-50. PubMed ID: 10594686
[TBL] [Abstract][Full Text] [Related]
37. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2'-deoxycytidine.
Yan WH; Lin AF; Chang CC; Ferrone S
Cell Res; 2005 Jul; 15(7):523-31. PubMed ID: 16045815
[TBL] [Abstract][Full Text] [Related]
38. Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma.
Naumova E; Mihaylova A; Ivanova M; Mihailova S
Cancer Immunol Immunother; 2007 Jan; 56(1):95-100. PubMed ID: 16547704
[TBL] [Abstract][Full Text] [Related]
39. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
40. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.
Marincola FM; Shamamian P; Alexander RB; Gnarra JR; Turetskaya RL; Nedospasov SA; Simonis TB; Taubenberger JK; Yannelli J; Mixon A
J Immunol; 1994 Aug; 153(3):1225-37. PubMed ID: 8027550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
